- Home
- RPGL vs OSRH Comparison
RPGL vs OSRH Comparison
Compare RPGL & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPGL
- OSRH
- Stock Information
- Founded
- RPGL 2015
- OSRH N/A
- Country
- RPGL Singapore
- OSRH United States
- Employees
- RPGL N/A
- OSRH N/A
- Industry
- RPGL Computer Software: Prepackaged Software
- OSRH
- Sector
- RPGL Technology
- OSRH
- Exchange
- RPGL Nasdaq
- OSRH Nasdaq
- Market Cap
- RPGL 14.7M
- OSRH 12.5M
- IPO Year
- RPGL 2025
- OSRH N/A
- Fundamental
- Price
- RPGL $0.52
- OSRH $0.49
- Analyst Decision
- RPGL
- OSRH
- Analyst Count
- RPGL 0
- OSRH 0
- Target Price
- RPGL N/A
- OSRH N/A
- AVG Volume (30 Days)
- RPGL 1.2M
- OSRH 2.2M
- Earning Date
- RPGL 12-02-2025
- OSRH 11-12-2025
- Dividend Yield
- RPGL N/A
- OSRH N/A
- EPS Growth
- RPGL N/A
- OSRH N/A
- EPS
- RPGL N/A
- OSRH N/A
- Revenue
- RPGL $396,737.00
- OSRH N/A
- Revenue This Year
- RPGL N/A
- OSRH N/A
- Revenue Next Year
- RPGL N/A
- OSRH N/A
- P/E Ratio
- RPGL N/A
- OSRH N/A
- Revenue Growth
- RPGL N/A
- OSRH N/A
- 52 Week Low
- RPGL $0.42
- OSRH $0.45
- 52 Week High
- RPGL $5.19
- OSRH $13.00
- Technical
- Relative Strength Index (RSI)
- RPGL N/A
- OSRH 39.89
- Support Level
- RPGL N/A
- OSRH $0.53
- Resistance Level
- RPGL N/A
- OSRH $0.61
- Average True Range (ATR)
- RPGL 0.00
- OSRH 0.06
- MACD
- RPGL 0.00
- OSRH -0.01
- Stochastic Oscillator
- RPGL 0.00
- OSRH 9.60
About RPGL Republic Power Group Limited Class A Ordinary Shares
Republic Power Group Ltd is a Singapore-based provider of customized software development, technology solutions, consulting, and technical support services. The company specializes in real-time monitoring, resource allocation, surveillance, and threat detection software, with capabilities in AI and IoT integration to provide services to corporate clients and government agencies.
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.